Loading
A phase 3 trial in pancreatic cancer, run by Helsinki University Central Hospital, not yet recruiting.
Neoadjuvant Treatment vs Upfront Surgery for Left-Sided Pancreatic Cancer is a phase 3, randomised interventional study registered as NCT07155629 by Helsinki University Central Hospital, with a registry enrolment figure of 381 participants, started 2025-09-01 and due to reach its primary completion in 2030-08-31. Interventions recorded: mFOLFIRINOX neoadjuvant chemotherapy / Nab-paclitaxel and gemcitabine. Conditions listed: Pancreatic Cancer Resectable. Primary outcome: Overall Survival. Pancreatic eligibility wording from the registry: "* Resectable left pancreatic cancer according to NCCN criteria". Sites: Finland. No results are recorded here; the registry entry is the source.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.
Shares Resectable pancreatic ductal adenocarcinoma, Pancreatic cancer trials open today (registry snapshot and UK sites) and the tag pancreatic-deep-dive.